Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

Similar articles for PubMed (Select 24117380)

1.

Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.

Ahmadi M, Ahmadihosseini Z, Allison SJ, Begum S, Rockley K, Sadiq M, Chintamaneni S, Lokwani R, Hughes N, Phillips RM.

Br J Pharmacol. 2014 Jan;171(1):224-36. doi: 10.1111/bph.12438.

2.
3.
4.

Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.

Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.

Cancer Chemother Pharmacol. 2006 Nov;58(5):577-84. Epub 2006 Mar 11.

PMID:
16532343
5.

EGFR plays a pivotal role in the regulation of polyamine-dependent apoptosis in intestinal epithelial cells.

Ray RM, Bhattacharya S, Johnson LR.

Cell Signal. 2007 Dec;19(12):2519-27. Epub 2007 Aug 15.

6.

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.

Cancer Res. 2006 Dec 15;66(24):11851-8.

7.

Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors.

Filippi I, Naldini A, Carraro F.

Curr Med Chem. 2011;18(19):2885-92. Review.

PMID:
21651491
8.

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.

Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R.

Cancer Res. 2008 Dec 1;68(23):9624-33. doi: 10.1158/0008-5472.CAN-08-1131.

9.

Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.

Lin YC, Wu MH, Wei TT, Chuang SH, Chen KF, Cheng AL, Chen CC.

Neoplasia. 2012 Jun;14(6):463-75.

10.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
12.

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.

Robert G, Jullian V, Jacquel A, Ginet C, Dufies M, Torino S, Pottier A, Peyrade F, Tartare-Deckert S, Bourdy G, Deharo E, Auberger P.

Oncotarget. 2012 Dec;3(12):1688-99.

13.

Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.

Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL.

Clin Cancer Res. 2009 Sep 15;15(18):5820-8. doi: 10.1158/1078-0432.CCR-08-3294. Epub 2009 Sep 8.

14.

Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.

Jameson MJ, Beckler AD, Taniguchi LE, Allak A, Vanwagner LB, Lee NG, Thomsen WC, Hubbard MA, Thomas CY.

Mol Cancer Ther. 2011 Nov;10(11):2124-34. doi: 10.1158/1535-7163.MCT-11-0294. Epub 2011 Aug 30.

15.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.

16.

Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.

Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.

World J Gastroenterol. 2012 Nov 21;18(43):6226-34. doi: 10.3748/wjg.v18.i43.6226.

17.

Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.

Du W, Zhou JR, Wang DL, Gong K, Zhang QJ.

World J Surg Oncol. 2012 Apr 21;10:60. doi: 10.1186/1477-7819-10-60.

18.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
19.

Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.

Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps TJ.

Blood. 2011 Jan 20;117(3):882-9. doi: 10.1182/blood-2010-04-282400. Epub 2010 Nov 15.

20.

Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.

Xiao Z, Ding N, Xiao G, Wang S, Wu Y, Tang L.

Anat Rec (Hoboken). 2012 Dec;295(12):2122-8. doi: 10.1002/ar.22552. Epub 2012 Aug 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk